MERCK & CO. INC. reported first-quarter revenue rose 5% to $16.3 billion, beating estimates of $15.8 billion. Strong demand for cancer drug Keytruda offset a $3.62-per-share charge from the Cidara Therapeutics acquisition. Investors are weighing Merck's ability to diversify revenue before Keytruda loses patent protection later this decade.

Pipeline Expansion Offsets Acquisition Costs